See also
ˇ Show More
The statement of financial position provides creditors, investors, and analysts with information on company's resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company's assets as well as an indication of cash flows that may come from receivables and inventories.
Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.
Abbott Laboratories, Consolidated Statement of Financial Position, Liabilities and Stockholders' Equity
USD $ in thousands
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | ||
|---|---|---|---|---|---|---|
 |
Short-term borrowings | 2,347,859 | 4,349,796 | 4,978,438 | 1,691,069 | 1,827,361 |
|
Trade accounts payable | 1,721,127 | 1,535,759 | 1,280,542 | 1,351,436 | 1,219,529 |
|
Salaries, wages and commissions | 1,260,121 | 1,328,665 | 1,117,410 | 1,011,312 | 859,784 |
|
Accrued rebates payable to government agencies | 1,049,000 | 900,000 | 641,000 | 577,000 | 661,822 |
|
Accrued other rebates | 1,238,000 | 862,000 | 668,000 | 455,000 | 444,633 |
|
All other | 5,567,994 | 4,252,772 | 3,054,032 | 3,184,742 | 2,606,649 |
|
Other accrued liabilities | 7,854,994 | 6,014,772 | 4,363,032 | 4,216,742 | 3,713,104 |
|
Dividends payable | 754,284 | 680,749 | 620,640 | 559,064 | 504,540 |
|
Income taxes payable | 514,947 | 1,307,723 | 442,140 | 805,397 | 80,406 |
|
Obligation in connection with conclusion of the TAP Pharmaceutical Products Inc. joint venture | – | – | 36,105 | 915,982 | – |
|
Current portion of long-term debt | 1,026,896 | 2,044,970 | 211,182 | 1,040,906 | 898,554 |
|
Current liabilities | 15,480,228 | 17,262,434 | 13,049,489 | 11,591,908 | 9,103,278 |
|
Long-term debt, excluding current portion | 12,039,822 | 12,523,517 | 11,266,294 | 8,713,327 | 9,487,789 |
|
Defined benefit pension plans and post-employment medical and dental plans for significant plans | 3,301,000 | 2,425,000 | 2,394,000 | 2,713,000 | 1,872,518 |
|
Deferred income taxes | 703,000 | – | – | – | – |
|
All other | 4,226,698 | 4,774,851 | 2,808,111 | 1,882,278 | 1,426,394 |
|
Post-employment obligations and other long-term liabilities | 8,230,698 | 7,199,851 | 5,202,111 | 4,595,278 | 3,298,912 |
|
Noncurrent liabilities | 20,270,520 | 19,723,368 | 16,468,405 | 13,308,605 | 12,786,701 |
|
Total liabilities | 35,750,748 | 36,985,802 | 29,517,894 | 24,900,513 | 21,889,979 |
|
Preferred shares, one dollar par value, none issued | – | – | – | – | – |
|
Common shares, without par value | 9,817,134 | 8,744,703 | 8,257,873 | 7,444,411 | 6,104,102 |
|
Common shares held in treasury, at cost | (3,687,478) | (3,916,823) | (3,310,347) | (2,626,404) | (1,213,134) |
|
Earnings employed in the business | 20,907,362 | 18,927,101 | 17,054,027 | 13,825,383 | 10,805,809 |
|
Accumulated other comprehensive income (loss) | (2,597,185) | (1,366,846) | 854,074 | (1,163,839) | 2,081,763 |
|
Abbott shareholders' investment | 24,439,833 | 22,388,135 | 22,855,627 | 17,479,551 | 17,778,540 |
|
Noncontrolling interests in subsidiaries | 86,312 | 88,329 | 43,102 | 39,140 | 45,405 |
|
Total shareholders' investment | 24,526,145 | 22,476,464 | 22,898,729 | 17,518,691 | 17,823,945 |
|
Total liabilities and shareholders' investment | 60,276,893 | 59,462,266 | 52,416,623 | 42,419,204 | 39,713,924 |
| Item | Description | The company |
|---|---|---|
| Trade accounts payable | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). | Abbott Laboratories's trade accounts payable increased from 2009 to 2010 and from 2010 to 2011. |
| Current liabilities | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. | Abbott Laboratories's current liabilities increased from 2009 to 2010 but then slightly declined from 2010 to 2011. |
| Noncurrent liabilities | Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle. | Abbott Laboratories's noncurrent liabilities increased from 2009 to 2010 and from 2010 to 2011. |
| Total liabilities | Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. | Abbott Laboratories's total liabilities increased from 2009 to 2010 but then slightly declined from 2010 to 2011. |
| Abbott shareholders' investment | Total of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). | Abbott Laboratories's abbott shareholders' investment declined from 2009 to 2010 but then increased from 2010 to 2011 exceeding 2009 level. |
| Total shareholders' investment | Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. | Abbott Laboratories's total shareholders' investment declined from 2009 to 2010 but then increased from 2010 to 2011 exceeding 2009 level. |
May 19, 2012